'On standalone basis
Quarter ended December 2024 compared with Quarter ended December 2023.
Net sales (including other operating income) of Pfizer has declined 0.37% to Rs 537.99 crore. Operating profit margin has declined from 28.25% to 27.14%, leading to 4.30% decline in operating profit to Rs 145.99 crore. Raw material cost as a % of total sales (net of stock adjustments) decreased from 13.24% to 13.10%. Purchase of finished goods cost fell from 25.48% to 20.44%. Employee cost increased from 15.32% to 18.74%. Other expenses fell from 19.80% to 19.30%.
Other income up 19.27% to Rs 42.76 crore. PBIDT rose 0.19% to Rs 188.75 crore. Provision for interest fell 47.20% to Rs 1.51 crore.
PBDT rose 0.92% to Rs 187.24 crore. Provision for depreciation down 15.67% to Rs 14.8 crore.
Profit before tax grew 2.65% to Rs 172.44...
Pleaselogin & subscribe to view the full report.
More Reports
-
Pricing pressures weighed on margins
-
-
-
|
|